5 studies found for:    7526212 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Ranibizumab Injections to Treat Macular Telangiectasia Without New Blood Vessel Growth
Condition: Macular Telangiectasia
Intervention: Drug: Ranibizumab
2 Completed Fractalkine, a CX3C Chemokine, Act as a Mediator of Ocular Angiogenesis
Conditions: Proliferative Diabetic Retinopathy;   Angiogenesis
Intervention:
3 Active, not recruiting Treat and Extend Treatment With 0.5mg Ranibizumab vs Monthly Treatment With 0.5mg Ranibizumab
Condition: Macular Degeneration
Intervention: Drug: 0.5mg ranibizumab
4 Completed
Has Results
Evaluation of Macugen Treatment of Macular Edema Due to Branch Retinal Vein Occlusion
Condition: Branch Retinal Vein Occlusion
Intervention: Drug: pegaptanib sodium (Macugen)
5 Completed Ranibizumab Injections to Treat Macular Telangiectasia With New Blood Vessel Growth
Condition: Neovascularization
Intervention: Drug: Ranibizumab

Indicates status has not been verified in more than two years